Published date: 10 July 2023
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Special-purpose road passenger-transport services - 60130000
Location of contract
S10 2JF
Value of contract
£73,258.44
Procurement reference
CF-1710700D0O000000rwimUAA
Published date
10 July 2023
Closing date
10 July 2023
Closing time
5pm
Contract start date
17 July 2023
Contract end date
21 July 2023
Contract type
Service contract
Procedure type
Competitive quotation (below threshold)
The buyer selects a group of potential suppliers to invite to tender.
This procedure can be used for procurements below the relevant contract value threshold.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
GUSTO (STH20772) is a study for bladder cancer patients. Patients will be randomised to receive either standard care or the intervention treatment, which is selected following gene expression subtyping. Some of the patients on the intervention arm will receive the two drugs Durvalumab & Tremelimumab. Durvalumab & Tremelimumab are being provided free of charge by AstraZeneca, however, they will need to be stored and distritubed to 20 UK sites (including STH) over a 4 year period. The aim of the study is to obtain information to understand whether this approach could improve outcomes and to guide the design of a larger subsequent trial.
Award information
Awarded date
8 June 2023
Contract start date
17 July 2023
Contract end date
21 July 2023
Total value of contract
£73,258.44
This contract was awarded to 1 supplier.
ROYAL FREE LONDON NHS FOUNDATION TRUST (PHARMACY)
Address
Clinical Trials Manufacturing and Supplies, Royal Free London NHS Foundation Trust, Service Level, Pond Street, London, NW3 2QG
Reference
None
About the buyer
Contact name
Kimberley Kay
Address
Clock Tower Building, Northern General Hospital
Sheffield
S5 7AU
GB
Telephone
+44 7773624391
Share this notice
Closing: 10 July 2023, 5pm
All content is available under the
